Gracell Biotechnologies Receives IND Clearance For Phase 1 Trial Of GC012F In Multiple Myeloma
Gracell Biotechnologies Inc. (GRCL) announced the FDA has cleared Investigational New Drug application, allowing the company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma.